Assembly Biosciences (ASMB) Total Current Liabilities (2010 - 2026)

Assembly Biosciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $35.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 24.95% year-over-year to $35.0 million in Q1 2026; TTM through Mar 2026 was $35.0 million, a 24.95% decrease from a year earlier, with the FY2025 full-year figure at $48.8 million, up 2.04% from the prior year.
• Total Current Liabilities slipped to $35.0 million in Q1 2026 per ASMB's latest filing, from $48.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $53.4 million in Q3 2025 and bottomed at $7.1 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $38.8 million (2024), against an average of $30.8 million.
• Across the five-year window, Total Current Liabilities sank 53.87% in 2023 and jumped 483.78% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $16.3 million in 2022, then jumped by 140.7% to $39.2 million in 2023, then grew by 21.87% to $47.8 million in 2024, then gained by 2.04% to $48.8 million in 2025, then retreated by 28.26% to $35.0 million in 2026.
• Per Business Quant, the three latest ASMB Total Current Liabilities figures stand at $35.0 million (Q1 2026), $48.8 million (Q4 2025), and $53.4 million (Q3 2025).